Expression of STOML2 Promotes Proliferation and Glycolysis of Multiple Myeloma Cells Via Upregulating PAI-1

Overview

Journal J Orthop Surg Res

Publisher Biomed Central

Specialty Orthopedics

Date 2021 Nov 14

PMID 34774067

Citations 1

Authors

Hongxia Zhang

Guangsheng Wu

Junjian Feng

Xiaohong Lu

Ping Liu

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the effects of STOML2 and the relationship between STOML2 and PAI-1 in the development of multiple myeloma (MM).

Methods: Cell proliferation was tested using CCK-8 assay and cell colony formation assay. Glucose consumption, lactate production and ATP level were measured using commercial kits. The mRNA and protein expression were assessed using quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting, respectively.

Results: Both mRNA and protein expression of STOML2 were upregulated in MM patients compared to healthy volunteers. CCK-8 and colony formation assays demonstrated that STOML2 silencing inhibited cell proliferation in MM cells. Knockdown of STOML2 reduced glucose consumption, lactate production and ATP/ADP ratios. STOML2 silencing by shSTOML2 led to reduced PAI-1 expression. Overexpression of PAI-1 reversed the inhibitory effects of shSTOML2 on MM cell growth.

Conclusion: Results from this study demonstrated that STOML2 silencing inhibits cell proliferation and glycolysis through downregulation of PAI-1 expression, suggesting a new therapeutic target for MM.

Citing Articles

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.

Oudaert I, Van der Vreken A, Maes A, de Bruyne E, de Veirman K, Vanderkerken K Exp Hematol Oncol. 2022; 11(1):49.

PMID: 36050788 PMC: 9438316. DOI: 10.1186/s40164-022-00303-z.

References

Yagci M, Sucak G, Haznedar R . Fibrinolytic activity in multiple myeloma. Am J Hematol. 2003; 74(4):231-7. DOI: 10.1002/ajh.10433. View

Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S . The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int. 2016; 113(27-28):470-6. PMC: 4973001. DOI: 10.3238/arztebl.2016.0470. View

Zhu W, Li W, Geng Q, Wang X, Sun W, Jiang H . Silence of Stomatin-Like Protein 2 Represses Migration and Invasion Ability of Human Liver Cancer Cells via Inhibiting the Nuclear Factor Kappa B (NF-κB) Pathway. Med Sci Monit. 2018; 24:7625-7632. PMC: 6213821. DOI: 10.12659/MSM.909156. View

Song L, Liu L, Wu Z, Lin C, Dai T, Yu C . Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-κB/MMP-9 pathway. J Pathol. 2011; 226(3):534-43. DOI: 10.1002/path.3008. View

Feng Q, Yao Q, Li B, Xie Y, Zhang H, Xu Z . Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma. J Cancer. 2020; 11(16):4907-4916. PMC: 7330679. DOI: 10.7150/jca.45146. View

Richardson P, Laubach J, Gandolfi S, Facon T, Weisel K, OGorman P . Maintenance and continuous therapy for multiple myeloma. Expert Rev Anticancer Ther. 2018; 18(8):751-764. DOI: 10.1080/14737140.2018.1490181. View

Wong N, De Melo J, Tang D . PKM2, a Central Point of Regulation in Cancer Metabolism. Int J Cell Biol. 2013; 2013:242513. PMC: 3586519. DOI: 10.1155/2013/242513. View

Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen M . STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol. 2021; 14(1):16. PMC: 7807703. DOI: 10.1186/s13045-020-01029-3. View

Li S, Wei X, He J, Tian X, Yuan S, Sun L . Plasminogen activator inhibitor-1 in cancer research. Biomed Pharmacother. 2018; 105:83-94. DOI: 10.1016/j.biopha.2018.05.119. View

10.

Brigle K, Rogers B . Pathobiology and Diagnosis of Multiple Myeloma. Semin Oncol Nurs. 2017; 33(3):225-236. DOI: 10.1016/j.soncn.2017.05.012. View

11.

Misiewicz M, Robak M, Chojnowski K, Trelinski J . [Correlations between ROTEM fibrinolytic activity and t-PA, PAI-1 levels in patients with newly diagnosed multiple myeloma]. Pol Merkur Lekarski. 2014; 36(215):316-9. View

12.

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

13.

Lapatsina L, Brand J, Poole K, Daumke O, Lewin G . Stomatin-domain proteins. Eur J Cell Biol. 2011; 91(4):240-5. DOI: 10.1016/j.ejcb.2011.01.018. View

14.

Wang D, Qi H, Li A, Deng F, Xu Y, Hu Z . Coexisting overexpression of STOML1 and STOML2 proteins may be associated with pathology of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020; 129(6):591-599.e3. DOI: 10.1016/j.oooo.2020.01.011. View

15.

Xiao B, Xie Z, Guo L, Wu J, Zhang H . Stomatin-like protein 2 expression is associated with clinical survival in patients with cervical cancer. Int J Clin Exp Pathol. 2015; 8(2):1804-9. PMC: 4396211. View

16.

Li X, He F, Yan S, Li Y, Cao Y, Huang C . Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study. Med Oncol. 2013; 31(1):763. DOI: 10.1007/s12032-013-0763-9. View

17.

Pawlyn C, Davies F . Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2018; 133(7):660-675. PMC: 6384187. DOI: 10.1182/blood-2018-09-825331. View